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Targeting tumor-specific metabolic adaptations is a promising anticancer strategy when tumor defense mechanisms
are restrained. Here, we show that redox-modulating drugs including the retinoid N-(4-hydroxyphenyl)retinamide
(4HPR), the synthetic triterpenoid bardoxolone (2-cyano-3,12-dioxooleana-1,9(11)-dien-28-oic acid methyl ester),
arsenic trioxide (As2O3), and phenylethyl isothiocyanate (PEITC), while affecting tumor cell viability, induce
sustained Ser9 phosphorylation of the multifunctional kinase glycogen synthase kinase 3β (GSK3β). The antioxidant
N-acetylcysteine decreased GSK3β phosphorylation and poly(ADP-ribose) polymerase cleavage induced by 4HPR,
As2O3, and PEITC, implicating oxidative stress in these effects. GSK3β phosphorylation was associated with up-
regulation of antioxidant enzymes, in particular heme oxygenase-1 (HO-1), and transient elevation of intracellular
glutathione (GSH) in cells surviving acute stress, before occurrence of irreversible damage and death. Genetic
inactivation of GSK3β or transfection with the non-phosphorylatable GSK3β-S9A mutant inhibited HO-1 induction
under redox stress, while tumor cells resistant to 4HPR exhibited increased GSK3β phosphorylation, HO-1
expression, and GSH levels. The above-listed findings are consistent with a role for sustained GSK3β
phosphorylation in a signaling network activating antioxidant effector mechanisms during oxidoreductive stress.
These data underlie the importance of combination regimens of antitumor redox drugs with inhibitors of survival
signaling to improve control of tumor development and progression and overcome chemoresistance.
Neoplasia (2014) 16, 710–722Address all correspondence to: Adriana Albini Ph.D., Infrastruttura Ricerca-Statistica
(I-RS), IRCCS Tecnologie Avanzate e Modelli Assistenziali in Oncologia, Arcispedale S.
MariaNuova, VialeUmberto I, 50-42123Reggio Emilia, Italy or FrancescaTosetti Ph.D.,
IRCCS Azienda Ospedaliera Universitaria AOU S. Martino-IST Istituto Nazionale
per la Ricerca sul Cancro, Largo Rosanna Benzi 10, 16132, Genoa, Italy. E-mail: adriana.
albini@asmn.re.it; francesca.tosetti@hsanmartino.it
1This article refers to supplementary materials, which are designated by Figures W1 to
W5 and are available online at www.neoplasia.com.
Received 6 March 2014; Revised 30 July 2014; Accepted 31 July 2014
© 2014 Published by Elsevier Inc. on behalf of Neoplasia Press, Inc. This is an open access
article under the CCBY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/3.0/).
1476-5586/14
http://dx.doi.org/10.1016/j.neo.2014.07.012Introduction
Recent innovative approaches to cancer chemoprevention and
treatment focus on tumor-specific metabolic adaptations as drug
targets. In particular, some redox drugs appear to deeply compromise
tumor bioenergetics [1]. Antitumor agents belonging to this class of
chemicals, including the chemopreventive agent N-(4-hydroxyphenyl)
retinamide (4HPR) [2], the synthetic triterpenoid 2-cyano-3,12-
dioxooleana-1,9(11)-dien-28-oic acid methyl ester (CDDO-Me;
RTA402 or bardoxolone methyl) [3], and phytochemicals such as
phenylethyl isothiocyanate (PEITC) [4], are under scrutiny in clinical
studies. Accordingly, patterns of the antioxidant machinery are currently
used as biomarkers in clinical trials for metabolic disorders and cancer.
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growth factor–activated phosphatidylinositol 3-kinase and AKT and by
transient activation of the mitogen-activated protein kinase p42/p44
MAPK (ERK1/2) through ras-mediated pathways. These signaling
molecules, and related transcription factors, are part of a stress-sensing
network that can modify the activity and expression of effectors involved
in redox homeostasis, in concert with modulation of glutathione (GSH)
metabolism and the activation of a battery of antioxidant enzymes [5].
The multifunctional glycogen synthase kinase 3β (GSK3β) is a key
convergence point of survival pathways mediated by Ser/Thr protein
kinases most related to PKA, PKG, PKC (AGC) kinases (AKT, protein
kinase C (PKC), and cAMP-dependent protein kinase (PKA)), ERK1/2,
and Wnt. Accordingly, GSK3β inhibitors are under clinical scrutiny in
both neurodegenerative disorders and in cardioprotection. GSK3β
activity depends on the balance between the activating Tyr216
phosphorylation and the inactivating phosphorylation at Ser9. Recent
evidence indicates that active GSK3β in tumors can be proapoptotic or
antiapoptotic depending on the cell type or subcellular localization [6].
Recent findings highlight a role for active GSK3β in cancer stem cell
maintenance [7], reinforcing the interest for GSK3β inhibitors in cancer
treatment.
We have previously shown that 4HPR and CDDO-Me induce
tumor cell death by ATP depletion and mitochondrial bioenergetic
failure leading to necrosis-like death, associated with inhibition of basal
or insulin-like growth factor-1 (IGF-1)–induced AKT phosphorylation
and disruption of IGF-1 survival function [8–10]. Here, we investigated
modulation of GSK3β phosphorylation and antioxidant enzyme
expression, in particular heme oxygenase-1 (HO-1), and poly(ADP-
ribose) polymerase (PARP) cleavage as a sign of apoptosis, in the same
responsive cellular models under pharmacologic redox stress. Our
results show that the redox imbalance induced by 4HPR and other
redox drugs in retinoblastoma Y79 cells and by CDDO-Me and 4HPR
in human prostate cancer cells is associated with increased Ser9
phosphorylation of GSK3β requiring glucose metabolism and results in
activation of a defense response involving the induction ofHO-1,GSH,
and nicotinamide adenine dinucleotide (phosphate) (NAD(P)H) [11]
levels. Remarkably, GSK3 gene silencing, or expression of the GSK3β-
S9A mutant, decreased HO-1 induction in CDDO-Me–treated cells.
These findings highlight a correlation between GSK3β Ser9 phosphor-
ylation and the antioxidant response, suggesting that redox stress
induced by either oxido-reductive or metabolic perturbation uses a
redox code that targets sensitive signaling pathways. The regulatory
network described here suggests that curtailing the energy demanding
antioxidant response could increase the efficacy of redox anticancer
drugs.
Materials and Methods
Cell Cultures and Reagents
Human retinoblastoma Y79 cells (ATCC HTB-18), androgen-
independent PC3 (ATCC CRL-1435), and DU145 (ATCC HTB-81)
human prostate adenocarcinoma cells were obtained from American
Type Culture Collection (ATCC) (Manassas, VA) and certified by the
InterlabCell LineCollection of the Biological Bank andCell Factory core
facility (member of the European BioBanking and Molecular Resources
Research Infrastructure), IRCCS AOU S. Martino-IST, (Genoa, Italy).
The cells were propagated inRPMI 1640 supplementedwith either 15%
(retinoblastoma cells) or 10% (prostate cancer cells) heat-inactivated FBS
and 2 mM glutamine. For adherent cultures, retinoblastoma cells wereseeded on poly-D-lysine–coated dishes for 24 hours and then transferred
to a chemically defined N1 medium (Invitrogen, Life Technologies,
Monza, Italy). 4HPR was kindly provided by Dr James A. Crowell,
Division of Cancer Prevention, National Cancer Institute (Bethesda,
MD) and Dr Gregg Bullard, McKessonBio (Rockville, MD). Cells were
treated with 4HPR dissolved in ethanol in a 10 mM stock solution.
Human recombinant IGF-1 (PeproTech EC, London, United
Kingdom) was diluted in 0.1 N acetic acid and used at the final
concentration of 10 to 100 ng/ml. In the experiments with IGF-1, the
cells were maintained for 24 hours in N1 defined medium without
insulin. The synthetic triterpenoid CDDO-Me was kindly provided by
DrMichael B. Sporn (Dartmouth Medical School, Hanover, NH). The
following reagents used were purchased from Sigma-Aldrich (Milano,
Italy): the antioxidants N-acetylcysteine (NAC), desferrioxamine
mesylate (DFX), and GSH ethyl ester (GSH-EE), the oxidants
As2O3, PEITC, and DL-buthionine-[S,R]-sulfoximine, and the
mitogen-activated protein kinase kinase (MEK) inhibitor bis[amino
[(2-aminophenyl)thio]methylene]butanedinitrile (U0126) from BIO-
MOL (Plymouth Meeting, PA); the p90 ribosomal S6 kinase
(p90RSK) inhibitor BI-D1780 was provided by Dario R. Alessi
(MRC Protein Phosphorylation Unit, University of Dundee,
Scotland, United Kingdom). All pretreatments with antioxidants
(NAC, DFX, and GSH-EE) or other reagents were carried out for 2
hours before drug administration.
Cell Viability and Cytotoxicity Assays
Cell viability was evaluated by the 3-(4,5-dimethylthiazol-2-yl)-2,5-
diphenyltetrazolium bromide (MTT) assay, by lactate dehydrogenase
release and ATP levels as previously described [8–10]. The absorbance
was determined with a microtiter plate reader (Molecular Devices
Corp, Sunnyvale, CA). Detection of cell membrane integrity was also
performed by propidium iodide staining (1 μg/ml) and flow cytometry
as previously described [9]. Analysis was performed on 10,000 gated
cells to exclude cell debris using a CyAn ADP flow cytometer
(Beckman Coulter, Milano, Italy).
Total and Reduced GSH Determination
Total GSH (reduced GSH plus glutathione disulfide (GSSG)) was
determined by the enzymatic recycling method with 5,5'-dithiobis-(2-
nitrobenzoic acid) (DTNB) (Ellman's reagent) (BioxyTech GSH-400
colorimetric assay; OxisResearch, Portland, OR). Total protein content
was determined before metaphosphoric acid precipitation by the DC
Protein Assay (Bio-Rad, Milano, Italy). Total GSH content was
calculated as nanomoles per milligram of protein and expressed as
percent relative to controls. Determination of GSH with monochlor-
obimane (mBCl; Molecular Probes, Life Technologies; 200 nM, 37°C
for 1 hour) was carried out in cells suspended in cold phosphate-
buffered saline using a microplate spectrofluorometer (SpectraMax
Gemini XPS; Molecular Devices) or by flow cytometry [12].
Reactive Oxygen Species Detection
The cells were incubated with 5 μMcarboxymethyl dichlorofluorescin
diacetate (CM-H2DCFDA) (Molecular Probes) 20 minutes before the
end of treatments and analyzed by flow cytometry as described [8,9].
Determination of Glucose Uptake
Glucose uptake was determined with the hydrolyzable fluorescent
probe (2-(N-(7-nitrobenz-2-oxa-1,3-diazol-4-yl)amino)-2-deoxy-D-
glucose (2-NBDG) and the nonhydrolyzable 6-NBDG (Molecular
Figure 1. 4HPR sustains GSK3β Ser9 phosphorylation in Y79 cells.
GSK3β phosphorylation correlates with PARP cleavage and AMPK
activation in cell death induced by 4HPR (2.5 μM). IGF-1 (100 ng/ml)
does not affect PARP cleavage. 4HPR inhibits IGF-1–induced AKT
phosphorylation at 24 hours.
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15 minutes and analyzed by flow cytometry in serum-free, phenol red–
free RPMI.
Determination of Glucose-6-Phosphate Dehydrogenase Activity
and NAD(P)H
The kinetics of glucose-6-phosphate dehydrogenase (G6PD) activity
was determined spectrophotometrically as previously described [14].
Cytosolic NAD(P)H levels in intact cells were determined according to
the method described by Rathmell et al. [11] adapted for flow cytometry.
Western Blot Analysis of Proteins
Total cell lysates were prepared with the Mammalian Cell Extraction
kit (MBL, Watertown, MA), supplemented with 1 mM sodium
orthovanadate. Protein quantification was performed with the DC
Protein Assay (Bio-Rad). Forty micrograms of total cellular proteins was
resolved on 12.5% sodium dodecyl sulfate–polyacrylamide gels and
transferred on polyvinylidene difluoride membranes (GE Healthcare,
Milan, Italy). The following antibodies were used: phospho–AKT-1
(Ser473), AKT, phospho-GSK3β (pGSK3β; Ser9), GSK3β, phospho–5'
adenosine monophosphate (AMP)-activated protein kinase (pAMPK;
Thr172), AMPK, full-length 116-kDa and 89-kDa cleavage fragment of
PARP (Asp214), phospho-ERK1/2, ERK1/2, Nrf2 (all from Cell
Signaling Technology, Beverly, MA); HO-1, GSH peroxidase, Cu/Zn
superoxide dismutase (SOD), G6PD (Stressgen, Enzo Life Sciences,
Milano, Italy); glutamate-cysteine ligase, catalytic subunit (GCLC)
(Abnova, c/o EMBL Enterprise Management Technology Transfer
GmbH (EMBLEM), Heidelberg, Germany); HRP-conjugated anti-
glyceraldehyde 3-phosphate dehydrogenase (GAPDH) (Novus Biolog-
icals Inc., Littleton, CO); secondary HRP-labeled antibodies (Cell
Signaling Technology). The ECL-Plus reagent was from GEHealthcare.
Immunohistochemistry
Immunohistochemical analysis was carried out on formalin-fixed,
paraffin-embedded 3-μm sections of prostate biopsies provided by the
Pathology Unit of our Institute. Citrate buffer (pH 6) was used for
antigen unmasking; endogenous peroxidase was inactivated by 3%
H2O2, and unspecific binding sites were blocked with goat serum.
Anti-pGSK3β (Cell Signaling Technology) and HO-1 (Stressgen)
antibodies were used at 10 μg/ml concentration and the reaction was
revealed with the anti-rabbit HRP-DAB Plus Ultravision Detection
System (Thermo Fisher Scientific, Freemont, CA).
RNA Interference and GSK3β Transfection
SignalSilence GSK3α/β target-specific and non-targeted control small
interfering RNAs (siRNAs) (Cell Signaling Technology) were used to
inhibit GSK3α/β as described [10]. The non-phosphorylatable
hemagglutinin–GSK3β-S9A pcDNA3 (Plasmid 14754; Addgene,
Cambridge, MA) was provided by Jim Woodgett (Mount Sinai
Hospital, Toronto,Canada) [15]. PC3 andDU145 cells were transfected
with the TransIT-TKO Transfection Reagent provided by Mirus Bio,
Corp (Madison,WI), kept in the presence of gentamicin (800μg/ml) for
15 days, and analyzed at intervals during the selection process.
Statistical Analysis
The statistical significance between two data sets expressed as means ±
SD was determined by a two-tailed unpaired Student's t test using the
PRISM GraphPad software. One-way analysis of variance followed by
Tukey-Kramer test was used in the analysis of three or more data sets.
P values were set as follows: *P b .05, **P b .01, and ***P b .001.Results
GSK3β Ser9 Phosphorylation Correlates with Cell
Death Activation
The anticancer drugs 4HPR and CDDO-Me induce tumor cell
death by bioenergetic failure due to loss of mitochondrial
transmembrane potential (Δψm), ATP depletion, cell membrane
damage, and down-regulation of the AKT survival pathway [9,10]. In
this study, we explored redox stress and survival signaling in the cell
death pathways induced by CDDO-Me in prostate adenocarcinoma
PC3 and DU145 cells and by 4HPR in Y79 retinoblastoma cells,
focusing on the role of GSK3β in these processes.
Treatment with 4HPR induced time-dependent GSK3β phos-
phorylation in Y79 cells that persisted at 24 hours and was coincident
with extensive PARP cleavage (Figure 1), in line with activation of
caspase-3, DNA fragmentation, and nuclear apoptosis in dying cells
[9]. Similar to the effects of CDDO-Me in prostate cancer cells [10],
4HPR in Y79 cells induced GSK3β phosphorylation that parallels
decreased AKT phosphorylation [9]. While AKT stimulation by IGF-
1 was inhibited by 4HPR, GSK3β Ser9 phosphorylation was
sustained (Figure 1). Perturbation of IGF-1 signaling by 4HPR
correlated with the lack of effect of IGF-1 on PARP cleavage. Reactive
oxygen species (ROS) elevation by 4HPR impairs cellular bioener-
getics in Y79 cells, as indicated by ATP depletion and disruption of
Δψm [9]. The master energy sensor AMPK can be activated during
redox stress concomitant with autophagy, hypoxia, and nutrient
deprivation [16]. Increased phosphorylation at Thr172 of AMPK and
its substrate acyl CoA carboxylase pACC at Ser79 confirmed that
GSK3β hyperphosphorylation plays a role in 4HPR-induced cell
death in critical energy conditions under redox stress.
GSK3β Ser9 Phosphorylation Is Associated with an
Antioxidant Response
GSK3β phosphorylation has been associated with cytoprotective
mechanisms to preserve homeostasis during metabolic stress [6].
Since 4HPR and CDDO-Me can kill tumor cells by redox stress
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increased expression of antioxidant enzymes. HO-1 catalyzes the rate-
limiting step in heme catabolism as an adaptive response to oxidative
injury. Cytosolic Cu/Zn SOD serves to detoxify ROS. G6PD, the
limiting enzyme of the pentose phosphate pathway (PPP), provides
reducing equivalents (NADPH). GSH peroxidase detoxifies peroxides
through GSH oxidation. Expression of all four pro-survival molecules
was upregulated in 4HPR-treated Y79 cells at 24 hours (Figure 2A).
Dose-dependent HO-1 and Cu/Zn SOD expression were induced in a
limited concentration range, declining with the severity of cell damageFigure 2. (A) Induction of antioxidant enzymes is associated with PA
was carried out by normalizing protein expression versus GAPDH a
vertical line indicates the junction between control and lanes s
phosphorylation and HO-1 and Nrf2 expression in 4HPR-treated Y79 c
and PARP processing in PC3 cells treated with 4HPR. (D) Dose-depen
caspase-8 processing in PC3 and DU145 cells treated with CDDO-M
previous results [10]. Pretreatment for 2 hours with the antioxid
phosphorylation, PARP cleavage, and HO-1 expression induced by
molecular pattern analyzed under the effect of PEITC. HO-1 overex
panels, results from representative experiments are shown.(Figure 2B) [9]. GSK3β can regulate the activity of the transcription
factor Nrf2, which in turn controls the expression ofG6PD,HO-1, and
enzymes of GSHmetabolism [17]. Indeed, Nrf2 was increased within a
defined range of concentrations and declined at higher doses of 4HPR
in Y79 cells (Figure 2B). Due to the potential clinical application of
HO-1 pharmacological targeting [18], we limited further analysis to this
enzyme. Oxidative stress triggered by 4HPR in prostate tumor cells has
been extensively studied [19]; however, the antioxidant response was
not explored. In PC3 cells, 4HPR (10 μM) induced time-dependent
HO-1 expression and GSK3β phosphorylation, along with PARPRP cleavage induced by 4HPR in Y79 cells. Densitometric analysis
nd calculation of fold increase over control samples. The dividing
pliced from the blot. (B) Dose-dependent increase of GSK3β
ells. (C) Time-dependent GSK3β phosphorylation, HO-1 expression,
dent GSK3β phosphorylation, HO-1 and Nrf2 expression, PARP and
e (24 hours). pAMPK induction indicates ATP decline, in line with
ant NAC (10 mM) (E) or DFX (200 μM) (F) decreases GSK3β
4HPR (2.5 μM, 24 hours). (G) Similar modulation by NAC of the
pression is visible with the combination of As2O3 and NAC. In all
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necrotic-like death [10]. A dose-dependent increase of pGSK3β in these
cells treated with CDDO-Me (Figure 2D) [10] was associated with
transient HO-1 expression and pAMPK increase, both declining in late
apoptotic cells showing strong caspase-8 processing (Figure 2D). In Y79
cells, CDDO-Me at relatively low dose (250-500 nM, 24 hours) caused
massive cell lysis and extensive PARP cleavage indicative of severe cell
damage [20], while GSK3β Ser9 phosphorylation or HO-1 expression
was not induced (Figure W1A).
To assess whether oxidative stress in general stimulates GSK3β
phosphorylation, we investigated the effects of different redox drugs and
antioxidants. Besides 4HPR, we used the clinically relevant prooxidants
PEITC (2.5μM) [4] and As2O3 (50μM) [21]. Cell viability, as assessed
by ATP levels, remarkably declined in Y79 cells treated with PEITC,
As2O3, and CDDO-Me (FigureW1B). PEITC and As2O3, similarly to
4HPR [9,22], increased ROS in Y79 cells (Figure W1C). CDDO-Me
can alter redox in different tumor types [23]; however, it did not
increase ROS in Y79 or in PC3 cells (Figure W1, C and D). The
antioxidantNAC (10mM) that provides L-cysteine released by esterases
for GSH synthesis and the iron chelator DFX (200 μM) [9,24], which
both prevented mitochondrial and lysosomal damage in Y79 cells [9],
effectively lowered GSK3β phosphorylation and HO-1 expression, as
well as PARP cleavage, induced by 4HPR in Y79 cells (2.5 μM,
24 hours; Figure 2, E and F). Limited PARP cleavage by DFX alone has
been associated with cytoprotective preconditioning in neuronal cells
[25]. PEITC (2.5 μM) [4] and As2O3 (50 μM) [21] stimulated GSK3β
Ser9 phosphorylation and PARP cleavage in Y79 cells at 24 hours
(Figure 2G). This effect was prevented by NAC, which also abrogated
HO-1 expression induced by PEITC in Y79 cells but further increased
HO-1 expression induced by As2O3 (Figure 2G). This paradoxical
effect could be due to the particular chemistry of reaction betweenGSH
and trivalent arsenic, producing arsenic radicals and GSH-arsenic
conjugates that inhibit GSH reductase (GR), blocking regeneration of
oxidized GSH [26]. Enhanced HO-1 expression by As2O3 in
combination with other antioxidants has been reported [27]. In
contrast, PEITC and its bioactivation products form GSH conjugates
that do not apparently inhibit GR [26,28]. Taken together, these data
suggest that GSK3β Ser9 phosphorylation occurs during acute redox
imbalance triggering cell death [9,10] and correlates with activation of a
transient antioxidant defense.
Redox Imbalance Affecting GSK3β Ser9 Phosphorylation
Involves ROS and GSH
Prevention of PARP cleavage induced by 4HPR, As2O3, and
PEITC by NAC in Y79 cells (Figure 2) prompted us to investigate
whether redox stress affecting GSK3β was associated with altered
GSH metabolism. Determination of reduced GSH with the
fluorescent probe mBCl [12] and flow cytometry analysis revealed
discrete subpopulations in Y79 cells, differing in size and structural
complexity (Figure 3, A and B). They were distinguished by different
mBCl mean fluorescence intensity (MFI; bright and dim fluorescence
cells, corresponding to about 50% and 25% of all gated cells,
respectively), as confirmed by fluorescence microscopy (Figure 3A,
right). A percentage of non-fluorescent cells (about 10% of the gated
population) represented neuronal precursors undergoing spontaneous
death upon differentiation [29] (Figure 3, A, left, and B). DL-
Buthionine-[S,R]-sulfoximine was used as control to test GSH
depletion. The existence of heterogeneous populations with different
levels of GSH in tumors and in cell lines has been reported [30]. TheMFI of the bright fluorescence population at 24 hours after 4HPR
administration was transiently elevated over controls (Figure 3C).
Interestingly, GSH increase at 24 hours in the bright population was
consistent with bell-shaped ROS kinetics that peaked at 6 hours and
progressively declined at 24 hours after 4HPR administration [9].
These data are in line with a transient adaptive increase of GSH that
can be associated with a biphasic response to lethal oxidative stress
[31]. The fraction of bright fluorescent cells declined in a dose- and
time-dependent manner, shifting in the dim and non-fluorescent
dying population (Figure 3B; data at 16 hours of treatment are not
shown). Thus, total GSH levels in the whole cell population treated
with 5 μM 4HPR was decreased to approximately 50% of controls at
24 hours (average decrease of 50.2 ± 10.6%; Figure 3D).
A significant reduction of total GSH (reduced GSH plus GSSG), as
determined with DTNB, was observed in Y79 cells after 24 hours of
treatment with 2.5μM4HPR (40.8 ± 0.5% of control; meanGSH levels
in controls were 10.16 ± 1.82 nmol/mg protein; Figure 3E), confirming
the data obtained with mBCl (Figure 3D). In the cells pretreated with
NAC (10 mM, 2 hours), intracellular total GSH was elevated over
controls, both in the absence or presence of 4HPR (Figure 3E), as
expected. Lack of effect of methionine to inhibit GSH efflux [32]
excluded that GSH decline was due to extracellular release (data not
shown). As2O3,andCDDO-Me substantially depletedGSH levels in Y79
cells, in contrast with PEITC that did not exert significant effects (Figure
W2A). In PC3 and DU145 prostate tumor cells, GSH was significantly
decreased by CDDO-Me at 24 hours of treatment (Figure W2B).
The Y79 bright and dim fluorescence populations were collected
by cell sorting. The bright population showed increased basal as well
as 4HPR-induced GSK3β phosphorylation relative to the total
population and was able to cleave PARP in response to 4HPR
(2.5 μM, 24 hours; Figure W2C). To assess whether intracellular
GSH content could influence GSK3β phosphorylation, we treated
the cells with a cell permeable GSH-EE (10 mM) for 16 and
24 hours. Cells treated with GSH-EE showed increased basal GSK3β
phosphorylation, consistent with the previous result. In contrast,
PARP cleavage, HO-1 expression (Figure W2D), and ROS induced
by 2.5 μM 4HPR (Figure W2E) were decreased, indicating
antioxidant effects similar to NAC. It is possible that NAC, also
capable of influencing energy metabolism [33], exerts a more tunable
effect on redox balance, while an abrupt uptake of GSH-EE could
result in reductive stress in Y79 cells [34]. Taken together, these data
suggest that GSK3β phosphorylation can signal redox perturbations,
including variation in GSH levels, away from the equilibrium state.
4HPR-Resistant Cells Show Elevated GSH Levels and
Enhanced GSK3β Phosphorylation
To clarify the function of GSK3β in redox stress, we analyzed
GSK3β phosphorylation in established 4HPR-resistant cells. Y79,
PC3, and DU145 cells surviving chronic administration of 4HPR
starting from 1 μM and progressively reaching the 2.5 to 5 μM
concentration range were isolated from long-term cultures and cloned
by limiting dilution (Figures 4 and W3) [22]. Y79 cells resistant to
2.5 μM 4HPR (Y79-R2.5) showed significantly limited damage
induced by 4HPR, as evaluated by MTT reduction and extracellular
lactate dehydrogenase (Figure W3, A and B) and PARP cleavage
(Figure 4A) relative to the wild-type (wt) cells. Basal GSK3β
phosphorylation was enhanced, while HO-1 expression was not
elevated over wt cells, suggesting a minor role for HO-1 in 4HPR
resistance in Y79 cells (Figure 4A). GSH and NAD(P)H were
Figure 3. (A) Determination of GSH with mBCl distinguishes Y79 cell subpopulations with different GSH content. Representative flow
cytometry histogram of cell subpopulations (bright fluorescence, dim fluorescence, and dying cells; left) and fluorescence microscope
image (right). The analysis of mBCl fluorescence was done on 10,000 gated cells. (B) The percentage of subpopulations as mean ± SD
was calculated from three independent experiments run in duplicate. (C) Relative GSH content in the bright fluorescence population at
24 hours. (D) Relative GSH in the whole-cell population at 24 hours. (E) GSH levels determined with DTNB in cells treated with 4HPR
(2.5 μM, 24 hours) and effects of 2-hour pretreatment with NAC (10 mM) or CHX (0.125 μg/ml). The relative GSH content was calculated
fromMFI data normalized versus controls set as 1 from three independent experiments run in duplicate. Results are expressed asmeans±
SD. ***P b .001 and **P b .01, statistically significant difference versus control samples at 24 hours; ###P b .001, statistically significant
difference versus samples treated with 4HPR alone.
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4HPR for 1 week relative to the wt cells (Figure 4B). PC3 and
DU145 cells resistant to 5 μM 4HPR (PC3-R5, DU145-R5) showed
increased GSK3β phosphorylation, HO-1 and GCLC expression
(Figure 4, C and E, respectively), and high basal GSH and NAD(P)
H levels relative to the wt cells (Figure 4, D and F), a result in line
with the stabilization of a pGSK3β-mediated redox-sensitive signaling
cascade in stressed PC3 and DU145 cells [10]. These data suggest
that increased GSK3β phosphorylation could be part of an adaptive
mechanism to tolerate long-term exposure to redox stress. This
observation was corroborated by immunohistochemical analysis of
human prostate tumor specimens showing elevated pGSK3β and
HO-1 levels (Figure W4), in line with the evidence that oxidative
stress parallels prostate tumor progression [35,36].
GSK3β Ser9 Phosphorylation Influences HO-1 Expression
To further investigate the role of GSK3β in redox remodeling, we
analyzed HO-1 expression in PC3 and DU145 cells transiently
transfected with an siRNA specific for GSK3α/β. Reduction of GSK3β
expression has been linked to increased cellular distress in CDDO-Me–
treated and untreated prostate cancer cells [10]. Since GSK3α can
compensate for lack of GSK3β in some functions [37] and the role of
GSK3α is poorly defined in cell death, we silenced both GSK3α andGSK3β to better evaluate the role of GSK3 in this context. We then
focused on GSK3β because of the expanding development of GSK3β
pharmacologic inhibitors in clinical settings, even if isoform-specific
GSK3 inhibitors are lacking. Treatment with CDDO-Me (1 μM) for
24 hours strongly induced HO-1 expression in wt and non-specific
siRNA-transfected prostate cancer cells, while HO-1 was significantly
decreased in GSK3β-depleted cells (Figure 5A). Similarly, transfection
with the non-phosphorylatable GSK3β-S9A mutant caused a marked
decline in HO-1 induction by 4HPR and CDDO-Me in the same cell
lines (Figure 5, B and D), an indication that GSK3β Ser9
phosphorylation signaling is crucial to regulate HO-1 induction.
PC3 cells stably transfected with the GSK3β-S9A mutant grew
slower relative to the mock-transfected cells and were more sensitive
to CDDO-Me and 4HPR treatment (Figure W3D). Both PC3 and
DU145 cells stably transfected with the GSK3β-S9A mutant showed
elevated levels of GSH and NAD(P)H [11] relative to controls
(Figure 5, C and E, respectively), suggestive of an adaptive mechanism
to compensate a precarious redox balance in these cells.
Glucose Metabolism Supports GSK3β Phosphorylation
Induced by Prooxidants
To resist redox stress, cells activate metabolic adaptations to feed
antioxidant defenses. Since GSK3β has been shown to play a role in
Figure 4. (A) Y79 retinoblastoma cells resistant to 4HPR show increased GSK3β phosphorylation that correlates with lack of PARP cleavage.
(B) GSH and NAD(P)H levels are increased in 4HPR-resistant Y79 cells (R2.5). Increased GSK3β phosphorylation and high basal HO-1 and
GCLC expression in PC3 (C) and DU145 (E) cells resistant to 4HPR (5 μM). GSH and NAD(P)H levels in PC3 (D) and DU145 (F) cells resistant to
5 μM 4HPR (R5). Data represent means ± SD from two flow cytometry analyses run in duplicate. ***P b .001 versus wt cells.
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metabolism. The glucose antagonist 2-deoxyglucose (2DG), a non-
hydrolysable glucose analog, blocks glycolysis but undergoes further
metabolism through the PPP. In Y79 cells, 2DG decreased GSK3β
phosphorylation and HO-1 expression during acute (24 hours)
exposure to 4HPR and As2O3 (Figure 6, A and B). Energy loss, in
particular ATP [9], in these conditions was confirmed by increased
Thr172 phosphorylation of AMPK, recently implicated in NADPH
balance under metabolic stress [39]. Glucose metabolism through the
oxidative PPP partly contributes to NADPH homeostasis in cells
under oxidative stress. As shown in Figure 2A, G6PD expression was
induced in Y79 cells treated with 4HPR. Indeed, G6PD activity, after
a transient up-regulation at 16 hours, declined at 24 hours after
4HPR administration (Figure 6C). Accordingly, the G6PD inhibitor
6-aminonicotinamide (6AN, 1 mM) decreased GSK3β phosphory-
lation and HO-1 induction by 4HPR (Figure 6D). The 89-kDa
PARP cleavage fragment was decreased by 2DG and 6AN (Figure 6,
A, B, and D). Anomalous regulation of PARP cleavage in caspase-
independent oxidative cell death, similar to that induced by 4HPR
[9], has been described [40]. These represent signs of cellular distress;
both 2DG (50 mM) and 6AN (1 mM) in glucose-containing
medium (5 mM glucose), alone or in combination with 4HPR,
remarkably decreased MTT reduction and ATP levels in Y79 cells(Figure 6E). In Y79 cells resistant to 4HPR, glucose metabolism, as
assessed by the uptake of the glucose analogue 6-NBDG or 2-NBDG
and flow cytometry, was higher relative to wt Y79 cells (Figure 6F), in
line with the elevated NAD(P)H levels (Figure 4B) [11]. The lack of
GSK3β phosphorylation in acutely stressed cells with impaired
glucose metabolism, coupled with the enhanced requirement for
glucose in 4HPR-resistant Y79 cells, suggests that GSK3β phosphor-
ylation is glucose-dependent under stress conditions.
ERK1/2 and RSK Are Implicated in GSK3β Phosphorylation
Induced by 4HPR in Y79 Cells
Phosphorylation of Ser9 on GSK3β and of Ser21 on GSK3α is
mainly operated by AKT. In Y79 and prostate cancer cells, AKT
phosphorylation was decreased by 4HPR and CDDO-Me, respec-
tively, possibly due to energy depletion and redox stress [41,42] that
we observed in both models [9,10] and ceramide production in the
case of 4HPR [43]. We then considered other possible stress-activated
pathways. GSK3 can fall under the control of ERK1/2 under
oxidative stress [44–46]. The role of ERK1/2 phosphorylation in cell
survival or death, depending on the duration of the signal, is well
documented [45–47]. ERK1/2 phosphorylation was sustained at
24 hours after 4HPR (2.5 μM) administration in Y79 cells
(Figure 7A). The MEK inhibitor UO126 decreased GSK3β
Figure 5. (A) GSK3α/β gene silencing lowers HO-1 induction by CDDO-Me (1 μM, 24 hours) in PC3 and DU145 cells. The potentiation of
CDDO-Me cytotoxicity in these conditions has been published previously [10]. Optical density of bands was normalized versus GAPDH
and fold increase expression was calculated relative to control samples set as 1. (B) Transfection with the GSK3β-S9A mutant decreases
HO-1 induced by 4HPR and CDDO-Me in PC3 cells. (C) PC3 cells transfected with the GSK3β-S9Amutant show elevated levels of GSH and
NAD(P)H. (D) Lower induction of HO-1 in DU145 cells transfected with the GSK3β-S9A mutant in response to 4HPR and CDDO-Me
treatment. (E) Elevated GSH and NAD(P)H levels in DU145–GSK3β-S9A cells relative to themock-transfected cells. *P b .05 and ***P b .001,
statistically significant difference between GSK3β-S9A mutants and mock-transfected cells.
Neoplasia Vol. 16, No. 9, 2014 GSK3 Regulates Cell Death and Survival Signaling Venè et al. 717phosphorylation, slightly lowered HO-1 expression, and inhibited
PARP cleavage (Figure 7A), suggesting a role in cell death for ERK1/2
[45]. Remarkably, UO126 rescued loss of viability and cell membranedamage and prevented GSH decrease induced by 4HPR at 48 hours
(Figure 7, B and C, respectively). Accordingly, NAC abolished
ERK1/2 phosphorylation in 4HPR-treated cells (Figure 7D).
Figure 6. Interference with glucose metabolism hinders GSK3β phosphorylation induced by 4HPR and As2O3. (A) Y79 cells were
pretreated with 2DG (50 mM) for 2 hours and then treated with 2.5 μM 4HPR for 24 hours. AMPK activation indicates energy depletion.
(B) Effects of 2DG on GSK3β phosphorylation induced by As2O3. (C) Transient elevation at 16 hours and decreased activity of G6PD at 24
hours after 4HPR administration. Results expressed as absorbance per minute per milligram of protein were normalized relative to
controls. ***P b .001, statistical significant differences between control and 4HPR-treated samples at 16 and 24 hours. (D) Effects of
G6PD inhibition by 6AN (1 mM). (E) Decreased MTT reduction and ATP depletion in Y79 cells pretreated with 2DG or 6AN for 2 hours and
treated with 4HPR for 24 hours (left). ***P b .001, statistically significant difference versus samples treated with 4HPR alone. (F) Glucose
uptake, as determined with the fluorescent glucose analogue 2-NBDG or 6-NBDG and flow cytometry analysis, in wt and 4HPR-resistant
Y79 cells. ***P b .001 and **P b .01.
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however, the negative or positive effects of ERK1/2 activity on GSH
levels are still a matter of debate [45,46]. GSK3β can be
phosphorylated at Ser9 by the stress-activated p90RSK. Phosphor-
ylation of p90RSK can be controlled by ERK1/2 but also by other
pathways including phosphatidylinositol 3-kinase and phosphoinosi-
tide-dependent kinase-1 (PDK-1) [48]. Phosphorylation at Thr356/
Ser360 of RSK3, which is activated and can phosphorylate GSK3β
under oxidative stress [44], was effectively elevated by 4HPR and
decreased by UO126 (Figure 7A). The specific p90RSK inhibitor BI-
D1780 [49] abolished 4HPR-stimulated GSK3β phosphorylation,
induced PARP cleavage alone and in combination with 4HPR,
abolished HO-1 induction more effectively than UO126, and
increased loss of viability caused by 4HPR (Figure 7, E and F),
suggesting a partially ERK1/2 independent, pro-survival role forRSK3 in Y79 cells. The data obtained indicate that acute oxidative
stress induced by 4HPR activates a signaling pathway with an ERK1/
2-dependent branch mainly involved in cell death and an RSK-
dependent cytoprotective branch, both converging on GSK3β
phosphorylation and influencing cell fate in Y79 cells.
Discussion
In the tumor cells analyzed here, we previously described a short-term
model of cell death due to bioenergetic failure [9,10]. In particular, in
prostate tumor cells we demonstrated that GSK3β genetic inactiva-
tion favors necrosis and ATP loss [10]. The data obtained in this
study show a relationship between GSK3β expression or phosphor-
ylation and the modulation of the antioxidant asset of the cell, in
terms of HO-1 expression and intracellular GSH, during oxidative
stress. The modulation of GSK3β phosphorylation, concomitant with
Figure 7. Analysis of signaling pathways regulating GSK3β phosphorylation in Y79 cells. (A) The MEK inhibitor UO126 decreases GSK3β
phosphorylation, PARP cleavage, HO-1, and p90RSK phosphorylation induced by 4HPR at 24 hours. (B) UO126 rescues loss of MTT
reduction and cell membrane damage, as measured by propidium iodide (PI) permeability, by 4HPR (2.5 μM) at 48 hours. The data shown
are means ± SD of three independent experiments run in duplicate. (C) UO126 preserves GSH levels. Data were collected at 48 hours of
treatment with 4HPR (2.5 μM) from three independent measurements run in duplicate. Means ± SD are shown. ***P b .001, statistical
significance of differences versus samples treated with 4HPR alone. (D) The antioxidant NAC inhibits sustained ERK1/2 phosphorylation
induced by 4HPR at 24 hours, an indication of redox control of ERK1/2 during oxidative stress. (E) The p90RSK inhibitor BI-D1780 inhibits
GSK3β phosphorylation, but not ERK1/2 phosphorylation, suggesting GSK3β regulation by p90RSK downstream ERK1/2. (F) BI-D1780 (10
μM) exacerbates 4HPR toxicity in Y79 cells (2.5 μM, 24 hours). ***P b .001, statistical significance of differences versus samples treated
with 4HPR alone.
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coordinated processes in line with a dual role of GSK3β in
cytoprotection and cell death [50]. Several lines of evidence support
this suggestion: 1) Short-term genetic depletion of GSK3β by siRNA
or transfection with the GSK3β-S9A mutant, both converging on
deficient GSK3β Ser9 signaling, decreased HO-1 induction in cells
during acute oxidative stress. 2) 4HPR-resistant retinoblastoma and
prostate cancer cells, representing models of adaptation to chronic
stress, showed elevated GSK3β phosphorylation, intracellular GSH,
and NADPH. 3) Antioxidants prevented GSK3β phosphorylation,
paralleled by inhibition of PARP cleavage, a marker of nuclearapoptosis. 4) In bioenergetic stress models due to impaired glucose
metabolism, GSK3β phosphorylation along with HO-1 expression
was decreased, and 4HPR cytotoxicity was increased.
Our data indicate that GSK3β responds to an ample array of redox
perturbations, however within a limited range of either oxidative or
reductive equilibrium. GSK3β Ser9 phosphorylation was modulated
by ROS-mediated signals in Y79 cells treated with 4HPR, PEITC,
and As2O3, in keeping with previous observations [44,51]. In
CDDO-Me–treated prostate tumor cells, where GSK3β Ser9
phosphorylation and HO-1 were induced, no ROS burst was
observed; however, in these cells GSH declined, an event shared with
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responded to GSH-EE treatment, possibly sensing a disproportionate
reducing milieu [34]. GSK3β might be part of a mechanism that
propagates signals of mitochondrial damage, independently of ROS
overproduction, coupled with thiol imbalance.
We speculate that one possible function of GSK3β is to alert
defenses against redox instability and that GSK3β phosphorylation
and coordinated redox changes, including HO-1 induction,
promoting apoptotic cell death and delaying necrosis in acute damage
(Figure W5). In fact, transient GSK3β genetic inactivation, which
exacerbates cell necrosis in apoptotic cells treated with CDDO-Me
[10], lowered the ability to induce HO-1. Interestingly, HO-1
expression has been shown to modulate apoptotic and necrotic cell
death pathways [52,53]. In this context, the antioxidant effects of
HO-1 could favor a reducing milieu required for caspase activation
[54]. Further, prostate tumor cells stably transfected with the GSK3β-
S9A construct competing with the endogenous GSK3β showed lower
levels of HO-1 under stress. Decreased HO-1 expression in cells
depleted of GSK3β or the GSK3β-S9A mutant might indicate that
GSK3β Ser9–mediated signaling is a crucial event to induce HO-1.
In GSK3β-S9A cells, elevated basal GSH and NADPH were
suggestive of an acquired tolerance to a precarious redox equilibrium
due to a pool of unphosphorylatable GSK3β-S9A during selection.
Our data indicate that modulation of GSK3β activity could help
preserve a balanced milieu and bioenergetic resources in severe
oxidative injury by enhancing redox cycling or stimulation of GSH
metabolism. This suggestion is supported by the data indicating that
acute exposure to 4HPR in Y79 cells stimulates transient elevation of
GSH and G6PD activity producing NADPH. NADPH, a cofactor of
GR, is provided by enhanced glucose metabolism through the PPP,
feeding the main antioxidant defense of the cell [55]. In line with this,
glucose metabolism inhibitors repressed GSK3β phosphorylation and
activation of the antioxidant response. Most importantly, glucose
uptake was enhanced in 4HPR-resistant Y79 cells, suggesting that
gradual stabilization of some of the antioxidant mechanisms activated
upon acute exposure was functional to the selection leading to drug
resistance. In 4HPR-resistant prostate clones, GSK3β phosphoryla-
tion, GSH, NAD(P)H, and HO-1 were elevated over the wt
counterparts, implying that GSK3β Ser9 phosphorylation helps adapt
to chronic redox and metabolic stress.
The function of GSK3β does not appear identical in retinoblastoma
Y79 and in the prostate tumor cells analyzed here. One major
difference might be the lack of caspase-8 in Y79 cells. In fact, GSK3β
inhibits caspase-8 [6], whose activation was enhanced by LiCl or
GSK3β gene silencing in CDDO-Me–induced prostate tumor cell
death [10]. Opposing roles for GSK3 in cell-specific apoptotic
programs, even in the same cell type, have been described [6,56]. In
non-tumor cells, GSK3β phosphorylation propagates survival signals
[6], and upon oxidative stress, the change in GSK3β phosphorylation
varies depending on the cell type. For example, in kidney cells oxidative
injury has been shown to mitigate GSK3β phosphorylation [57].
Accordingly, GSK3β inhibitors are used in clinical trials for
neurodegenerative and cardiovascular disorders [6]. In several tumor
models, GSK3β has been proposed as a tumor suppressor [58,59]; in
contrast, GSK3β promotes tumorigenesis and development of ovarian,
colon, liver, and pancreatic carcinomas. In prostate tumor cells, GSK3β
inactivation is regarded as a potential therapeutic target [6,10].
The definition of the molecular events leading to persistent
GSK3β phosphorylation and related redox remodeling requiresfurther investigation. In Y79 cells, the result that the MEK inhibitor
UO126 preserves cell viability and GSH in 4HPR-stressed cells
indicates that pro-survival RSK signaling [44] is partly independent
of ERK1/2 in this GSK3β-mediated regulatory network. Reciprocal
regulation between GSK3β, ERK1/2, and RSK has been described
[60,61] (Figure W5). In this context, hyperresponsive signaling and
inadequate inactivation of ERK1/2 could contribute to the severity
of cell damage; however, we cannot exclude that redox imbalance
inactivates redox-sensitive protein phosphatases [62]. GSK3β has
been shown to regulate Nrf2 activity, allowing up-regulation of
antioxidant phase II genes including HO-1 and GSH regulators
[17]. The transient induction of Nrf2 we observed is suggestive of a
functional adjustment mediated by GSK3β phosphorylation,
possibly by catalyzing the formation of a phosphodegron [17], to
adapt GSH metabolism and HO-1 expression during acute
oxidative stress.
Tumor-specific oxidative stress received attention as a promising
therapeutic target [1,63]. Clinicopathologic traits of constitutive
oxidative stress in retinoblastoma [64,65] have encouraged clinical
studies of redox therapeutics, including As2O3. Chemopreventive
derivatives of natural redox compounds like 4HPR, CDDO-Me, and
PEITC have been shown to prompt homeostatic repair in early stages
of carcinogenesis, while inducing tumor cell death [63,66]. The data
presented here suggest that the energetic resources needed to
counteract acute cell damage conflict with the high metabolic
demand of frank tumor cells, eventually leading to tumor cell death.
In contrast, adaptation to chronic stress in drug-resistant cells stably
engages some of the same homeostatic antioxidant mechanisms
(Figure W5). Cell stress evokes interweaved events, after which the
severity of damage or successful channeling of cytoprotective signaling
and effector mechanisms prevails. In this context, our novel
observations on drug resistance assign a role for GSK3β in redox
remodeling to determine cell fate.
Supplementary data to this article can be found online at http://dx.
doi.org/10.1016/j.neo.2014.07.012.
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